AzTrials
AzTrials

Chronic Obstructive Pulmonary DiseaseNCT04683952

Rehabilitation With HHFNC in COPD in Nocturnal NIV

A study testing Exercise training with Humified High Flow Nasal Cannula in people with Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Humidified High Flow Nasal Cannula (HHFNC), with optional supplemental oxygen delivery, has evolved in recent years with an increasing number of papers that show a better meet with respiratory demand, decrease oxygen dilution, increased Functional Residual Capacity (FRC), dead space washout, more tolerate than Non… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Chronic Obstructive Pulmonary Disease
What is being tested?
Exercise training with Humified High Flow Nasal Cannula
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteItaly
Study dates
1 Jan 2020to Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of Chronic Obstructive Pulmonary Disease (post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) <0.7) ;
  • Nocturnal Non Invasive Ventilation (NIV) prescription according to ATS/ERS guidelines with or without long-term oxygen therapy;
  • Clinical stability (no exacerbation and no changing in respiratory drugs in the last 7 days);

Who cannot join

  • Orthopedic or neurological pathologies that limit physical performance;
  • Cognitive impairment (Mini-Mental State Examination <24);
  • Advanced heart disease, pulmonary fibrosis, participation in other clinical studies in the six months preceding the start of the study.

Trial locations and contacts

1 site in 1 country.

Paolo Banfi, MD contact

02 40308812

pabanfi@dongnocchi.it

Laila Di Pietro, RT contact

02 40308570

ldipietro@dongnocchi.it

Italy1 site, 1 recruiting
  • IRCCS Santa Maria Nascente, Fondazione Don Carlo Gnocchi

    Milan, 20148

    Paolo Banfi, MD, 0240308812 ext. 0039, pabanfi@dongnocchi.it

    Laila Di Pietro, RT, 024038570 ext. 0039, ldipietro@dongnocchi.it

    Recruiting

Other trials in Italy

About this study

Official title: Efficacy of Exercise Training With Humified High Flow Nasal Cannula, in Patients With Chronic Obstructive Pulmonary Disease Already in Nocturnal Non-Invasive Ventilation

Humidified High Flow Nasal Cannula (HHFNC), with optional supplemental oxygen delivery, has evolved in recent years with an increasing number of papers that show a better meet with respiratory demand, decrease oxygen dilution, increased Functional Residual Capacity (FRC), dead space washout, more tolerate than Non Invasive Ventilation (NIV) and provide heated and humidified gas. HHFNC is mainly used in intensive care settings or in acute respiratory diseases for the treatment of mild to moderate acute hypoxic respiratory failure and ventilator weaning. The aim of this study is to evaluate, in patients with Chronic Obstructive Pulmonary Disease (COPD) in nocturnal NIV, according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines, whether HHFNC during rehabilitation has an additional effect in increasing the distance in 6 Minute Walking Distance (6MWD) compared to the control group with nocturnal NIV without HHFNC treatment. As secondary objectives, we expect a decrease in Emergency Department (ED) accesses, General Practitioner (GP) unplanned visits, hospitalizations and an improvement of the quality of life and patient satisfaction.

Read the detailed description

RECRUITMENT PHASE: A qualified physiotherapist will check patient lists daily with the aim of identifying suitable candidates for the study.

The patients will be enrolled from January 2020 till june 2021 and they will be stratified individually and randomized by a dedicated software (https://www.randomizer.org/) into two groups:

  • Experimental group - Chronic Obstructive Pulmonary Disease (COPD) patients in nocturnal Non Invasive Ventilation (NIV) underwent to respiratory rehabilitation with Humidified High Flow Nasal Cannula (HHFNC) with / without Oxygen Therapy (O2), according to medical prescription;
  • Control group - patients in nocturnal NIV underwent to respiratory rehabilitation without HFNC with / without O2, according to medical prescription.

Before randomization, individual clinical inclusion and exclusion criteria will be taken into account in relation to the ability of each patient to tolerate the administration of the high flow ventilation program foreseen by the study.

RUN IN PHASE: After the assessment, each patient will perform a training session prior to the cycle ergometer, during which the subject will work on the workload and the established flow. The intensity of the workload will be 60-80% of the Wmax, calculated with the Hill's formula:

Wmax = ( 0.122 x 6MWD) + (72, 683 x Height) - 117.109

(where 6MWD is the distance walked on the 6-minute walk test, and the patient's height must be expressed in meters).

NIV and HHFNC will be administered through VEMO 150 (EOVE SA. 64000 Pau - France), a device with which it is possible setting up to 4 different ventilation programs. The High Flow can be delivered, as a continuous flow through the humidified nasal cannulas, up to 60 L / min with or without additional oxygen therapy according to medical prescription. The patients of the experimental group will be trained with the most adequate continuous flow, in a range between 20 and 60 L/min, according to the maximum flow supported by the patient.

FOLLOW UP PHASE: Outpatient rehabilitation will be performed in 3 cycles, each cycle in 40-minute sessions, 3 times a week. Each session starts with the cycle ergometer with a 5-minute warm-up to an intensity of 0 watts, continues with a 30-minute resistance training phase at a continuous target intensity (60-80% Wmax), then a warm-down of 5 minutes at an intensity of 0 watts.

The rehabilitation will be followed by a three-month washout period, for 3 cycles.

MEASUREMENTS: We have identified four periods to evaluate gas exchange, Forced expiratory volume in one second (FEV1) and respiratory muscle strength, dyspnea, exercise capacity, the presence of obstructive/central sleep apnea, prediction of mortality, activities of daily life, the impact of the disease and the quality of life.

These four periods are:

  • T0: baseline;
  • T1: at the end of the first rehabilitation cycle;
  • T2: at the end of the second rehabilitation cycle;
  • T3: at the end of the third rehabilitation cycle.

At the beginning of the study, demographics and clinical characteristics of eligible study participants will be collected.

Patients will be evaluated for:

  • Blood gas analysis (BGA) in T0, T1, T2, T3;
  • Spirometry: Forced Vital Capacity (FVC), FEV1 and FEV1/FEVC% in T0, T3;
  • Questionnaire of the British Medical Research Council (MRC) modified, in T0, T1, T2, T3;
  • Basic / Transition Dyspnea Index (BDI / TDI), in T0, T1, T2, T3;
  • 6 Minute Walking Distance (6MWD) with / without oxygen therapy, according to the medical prescription during the effort, in T0, T1, T2, T3;
  • COPD Assessment Test (CAT) in T0, T1, T2, T3;
  • Night time Polygraph to detect apnea/hypopnea, in T0, T3 ;
  • BODE INDEX (where BODE means body mass index, obstruction of air flow, dyspnoea and exercise capacity), in order to estimate the probability of survival, in T0, T1, T2, T3;
  • Saint George Respiratory Questionnaire (SGRQ) to investigate the quality of life in T0 and T3;
  • Evaluation of the perception of muscle fatigue and dyspnea (Borg RPE) and Visual Analogue Scale (VAS) each session.

During training, and the run-in phase, the physiotherapist will take note of FiO2 and of the dyspnea at the beginning and end of the session through VAS / BORG and again when the patient will be evaluated in 6MWD).

Being tested
Exercise training with Humified High Flow Nasal Cannula, Exercise training - Control Group
Keywords
COPD, HHFNC, Chronic Obstructive Pulmonary Disease, Humidified High Flow Nasal Cannula, Non Invasive Ventilation
Medical subject headings
Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise training with Humified High Flow Nasal CannulaDevice

    Also called VEMO 150

    The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.

  • Exercise training - Control GroupOther

    The control group will perform exercise training in spontaneous breathing.

Study groups in NCT04683952
Study groupRoleWhat they receive
Rehabilitation with HHFNCExperimental15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC). The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months.
Receives: Device: Exercise training with Humified High Flow Nasal Cannula
Control Group rehabilitation without HHFNCActive comparator15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC). The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months.
Receives: Other: Exercise training - Control Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in 6MWD

    The first outcome we expect to find is a change in the distance at 6-Minute Walking Distance (6MWD).

    Measured: "Baseline ( pre-intervention)" and "Immediately after the intervention".

Secondary outcomes (1)
  1. Number of Exacerbations, GP visits and admission to ED and ICU

    The second outcome is change of COPD exacerbation as admission to the Intensive Care Unit (ICU), to the admission to the ED with/without hospitalization, Generale Practitioner (GP) unplanned visits.

    Measured: Through study completion, an average of 1 year.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2020
  2. Study start1 Jan 2020
  3. Primary completionJan 2021 (estimated)
  4. Study completionJan 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04683952
Sponsor's protocol ID
FDG_HFNC_COPD_01
Status last verified
May 2020
First submitted
21 May 2020
Last updated
24 Dec 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol. 2014 Aug 7;14:66. doi: 10.1186/1471-2253-14-66. eCollection 2014.

    PubMed 25110463
  • Stephan F, Berard L, Rezaiguia-Delclaux S, Amaru P; BiPOP Study Group. High-Flow Nasal Cannula Therapy Versus Intermittent Noninvasive Ventilation in Obese Subjects After Cardiothoracic Surgery. Respir Care. 2017 Sep;62(9):1193-1202. doi: 10.4187/respcare.05473. Epub 2017 Aug 14.

    PubMed 28807988
  • Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7. doi: 10.1016/j.apmr.2008.01.020.

    PubMed 18760164
  • Ergan B, Oczkowski S, Rochwerg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. Print 2019 Sep.

    PubMed 31467119

Questions about this trial

What is this clinical trial studying?

A study testing Exercise training with Humified High Flow Nasal Cannula in people with Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Paolo Banfi, MD (02 40308812, pabanfi@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in 6MWD (time frame: "Baseline ( pre-intervention)" and "Immediately after the intervention".). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04683952, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in